Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast Cancer
This livestream continues the conversation from St.Gallen International Breast Cancer Conference 2023 on managing patients with HR-positive, HER2-negative early breast cancer. Learn to appropriately identify patients at high risk of recurrence and how to select optimal therapies based on latest scientific data, the latest guideline recommendations, and how to control adverse events.
We encourage all healthcare professionals to leverage information from this livestream to improve patient outcomes and minimize adverse events.
This livestream is supported by an unrestricted educational grant from Eli Lilly and Company.